PEX11B

Across TCGA pan-cancer cohorts, PEX11B mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated PEX11B data layer compared with 20 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher PEX11B mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PEX11B expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

HNSC, PDAC, and GBM are the cancer types where PEX11B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	All	0.698	1.000	.020	12	view →
PDAC	OS	Median	III,IV	0.578	0.301	.006	12	view →
GBM	DFS	Quartile	All	0.266	0.548	.001	10	view →
CCRCC	OS	Median	III,IV	0.202	0.985	.007	8	view →
LUAD	OS	Median	III,IV	0.828	0.267	.033	2	view →
LSCC	DFS	Quartile	All	1.000	0.510	.026	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

PEX11B–HNSC (DFS)

Open the HNSC breakdown →